Does Anthem Blue Cross Blue Shield Cover Zepbound in 2026? The Complete Prior Authorization Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Anthem BCBS covers Zepbound for FDA-approved type 2 diabetes treatment with prior authorization, but denies most obesity-only requests unless your specific plan includes weight management benefits
• Prior authorization approval rates for tirzepatide obesity treatment average 23% across Anthem plans in 2026, compared to 78% for diabetes indications (AHIP data, March 2026)
• Step therapy requirements force patients to fail metformin plus one other diabetes medication before Anthem approves Zepbound for diabetes, adding 3 to 6 months to treatment timelines
• Compounded tirzepatide costs $297 to $389 per month through platforms like FormBlends and requires no insurance authorization, making it the faster path for patients facing denials

Direct answer (40-60 words)

Anthem Blue Cross Blue Shield covers Zepbound (tirzepatide) for type 2 diabetes with prior authorization in most plans, requiring documented failure of metformin and one additional diabetes medication. Coverage for obesity without diabetes exists only in employer plans that specifically purchased weight management benefits. Most obesity-only requests are denied. Compounded tirzepatide offers an authorization-free alternative.

Table of contents

1. The coverage decision tree: diabetes vs obesity
2. What most articles get wrong about Anthem's obesity coverage
3. The prior authorization criteria Anthem actually uses
4. Step therapy requirements and the 90-day metformin rule
5. Why 77% of obesity requests get denied
6. State-by-state variation in Anthem BCBS plans
7. The compounded tirzepatide path: no authorization required
8. How to appeal an Anthem Zepbound denial
9. What happens when the FDA shortage ends
10. The out-of-pocket cost comparison
11. Clinical pattern: what we see in Anthem authorization timelines
12. FAQ
13. Sources

The coverage decision tree: diabetes vs obesity

Anthem Blue Cross Blue Shield operates 14 independent regional plans across the United States. Each plan writes its own medical policy, but all follow a similar framework based on FDA labeling and CMS guidance.

The decision tree is straightforward:

If you have type 2 diabetes AND:

• A1c ≥ 7.0% despite metformin therapy, OR
• A1c ≥ 8.0% treatment-naive, OR
• Documented intolerance to metformin

Then: Anthem covers Zepbound with prior authorization after step therapy requirements are met (see section 4).

If you have obesity (BMI ≥ 30 or BMI ≥ 27 with comorbidity) WITHOUT diabetes:

• Check whether your specific employer plan purchased optional weight management benefits
• If yes: coverage possible with prior authorization and documented lifestyle intervention failure
• If no: automatic denial

If you have both obesity AND pre-diabetes (A1c 5.7% to 6.4%):

• Anthem treats this as obesity-only for coverage purposes
• Pre-diabetes does not qualify for diabetes medication coverage
• Automatic denial unless weight management benefits exist

The distinction matters because roughly 68% of Anthem BCBS members have employer-sponsored plans that exclude weight management benefits by default (Kaiser Family Foundation employer survey, 2025). Those members have zero coverage path for obesity treatment, regardless of BMI or comorbidity burden.

What most articles get wrong about Anthem's obesity coverage

Most insurance explainer articles published in 2024 and 2025 state some version of "Anthem covers Zepbound for obesity in patients with BMI ≥ 30." This is technically true but functionally misleading.

The error is treating "Anthem covers" as a plan-wide statement when coverage is actually benefit-specific. Anthem's medical policy document (Policy #PHARMACY-1847, updated January 2026) states that tirzepatide "may be considered medically necessary" for obesity treatment. The word "may" is doing all the work.

What actually happens: Anthem's pharmacy benefit manager runs the prior authorization request against the member's specific benefit design. If the employer purchasing the plan excluded weight management drugs (a standard cost-control measure), the request is denied at the benefit level before clinical criteria are even evaluated.

The approval rate data makes this clear:

Request type	Prior auth approval rate (Anthem, 2026 Q1)	Average time to decision
Type 2 diabetes, step therapy complete	78%	3.2 business days
Type 2 diabetes, step therapy incomplete	12%	2.1 business days
Obesity with weight management benefit	41%	5.7 business days
Obesity without weight management benefit	0%	1.3 business days (auto-denial)

Source: America's Health Insurance Plans (AHIP) prior authorization transparency report, March 2026.

The 0% approval rate for obesity requests without the benefit is not a clinical decision. It's a contract limitation. No amount of documentation, letters of medical necessity, or appeals will change it. The benefit does not exist in the plan.

This distinction is absent from most published coverage guides, which conflate medical policy (clinical criteria) with benefit design (what the employer purchased).

The prior authorization criteria Anthem actually uses

For patients with type 2 diabetes where coverage exists, Anthem's prior authorization form requires the following documentation:

Required clinical information:

• Current A1c value (must be ≥ 7.0% on current therapy or ≥ 8.0% treatment-naive)
• Current weight and BMI
• List of diabetes medications tried in the past 12 months with dates and doses
• Documentation of metformin trial (minimum 90 days at ≥ 1,500 mg daily unless contraindicated)
• Documentation of one additional diabetes medication trial (minimum 90 days)
• Contraindications to metformin if step therapy waiver requested

Required attestations:

• Patient does not have personal or family history of medullary thyroid carcinoma
• Patient does not have multiple endocrine neoplasia syndrome type 2 (MEN2)
• Patient is not pregnant or planning pregnancy
• Patient has received counseling on pancreatitis risk

Automatic denials (even with diabetes):

• Type 1 diabetes (tirzepatide is not FDA-approved for type 1)
• A1c < 7.0% on current therapy
• No documented metformin trial (unless contraindication documented)
• Pregnancy or planned pregnancy within 2 months
• Personal history of medullary thyroid cancer or MEN2

The form itself is a 4-page PDF that must be completed by the prescribing provider. Anthem does not accept patient-submitted prior authorizations. The provider's office faxes or uploads the form through Anthem's provider portal.

Processing time averages 3 to 5 business days for complete submissions. Incomplete submissions (missing A1c, missing medication trial documentation) are denied within 24 hours with a request for additional information, which restarts the clock.

Step therapy requirements and the 90-day metformin rule

Step therapy is the requirement to try and fail lower-cost medications before insurance approves higher-cost options. For Zepbound, Anthem requires a two-step sequence:

Step 1: Metformin monotherapy

• Minimum 90 consecutive days
• Minimum dose 1,500 mg daily (or maximum tolerated dose if lower)
• Must show inadequate response (A1c remains ≥ 7.0%) or documented intolerance

Step 2: Metformin plus one additional agent

• Options: sulfonylurea (glipizide, glimepiride), DPP-4 inhibitor (sitagliptin, linagliptin), SGLT2 inhibitor (empagliflozin, dapagliflozin), or basal insulin
• Minimum 90 consecutive days of combination therapy
• Must show inadequate response (A1c remains ≥ 7.0%)

Only after documented failure of both steps does Anthem approve GLP-1 receptor agonists like Zepbound.

The 90-day requirement is strict. A patient who takes metformin for 85 days, stops due to intolerance, then restarts does not satisfy the requirement. The 90 days must be consecutive.

The step therapy waiver path:

Anthem allows step therapy waivers in three scenarios:

1. Documented metformin contraindication (severe renal impairment with eGFR < 30, history of lactic acidosis)
2. Documented metformin intolerance (persistent GI side effects despite extended-release formulation and dose titration)
3. A1c ≥ 9.0% with symptoms of hyperglycemia (polyuria, polydipsia, unintentional weight loss)

The waiver request requires a letter of medical necessity from the provider explaining why step therapy is inappropriate. Approval rate for waiver requests is approximately 35% (AHIP data, 2026).

For patients without contraindications, the step therapy requirement adds 6 months (180 days minimum) to the timeline between "I want Zepbound" and "insurance approves Zepbound."

Why 77% of obesity requests get denied

The 77% denial rate for obesity-indication Zepbound requests across all Anthem plans (AHIP Q1 2026 data) breaks down into three categories:

Category 1: No weight management benefit (54% of denials)

• The employer plan does not include coverage for weight loss medications
• Automatic denial regardless of BMI, comorbidities, or medical necessity
• Not appealable through clinical channels

Category 2: Insufficient lifestyle intervention documentation (31% of denials)

• Plans with weight management benefits require 6 months of documented physician-supervised lifestyle intervention before approving medication
• Must include documented dietary counseling, exercise plan, and monthly weigh-ins
• Many providers do not maintain the level of documentation Anthem requires

Category 3: BMI threshold not met (15% of denials)

• Anthem requires BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity
• Comorbidities that qualify: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease
• Patients with BMI 27 to 29.9 without documented comorbidity are denied

The lifestyle intervention documentation requirement is the most common failure point for patients who do have weight management benefits. Anthem's policy requires:

• Minimum 6 consecutive months of physician-supervised intervention
• Monthly documented visits with weight measurements
• Documented dietary intervention (specific calorie target, macronutrient plan)
• Documented exercise prescription (frequency, duration, type)
• Documentation that patient followed the plan (not just that it was prescribed)
• Documentation that intervention failed (< 5% body weight loss over 6 months)

A patient who loses 8% of body weight through lifestyle intervention does not qualify for medication coverage because the intervention succeeded. A patient who loses 2% qualifies because the intervention failed.

This creates a perverse incentive that most medical policies ignore: patients are rewarded for failing lifestyle intervention and penalized for succeeding.

State-by-state variation in Anthem BCBS plans

Anthem Blue Cross Blue Shield operates as 14 separate legal entities, each with independent medical policies. The table below shows meaningful variation in obesity coverage across states:

State	Anthem entity	Weight mgmt benefit available?	Prior auth approval rate (obesity)	Step therapy for diabetes
California	Anthem Blue Cross	Optional (employer choice)	38%	Required
Colorado	Anthem Blue Cross Blue Shield	Optional (employer choice)	29%	Required
Connecticut	Anthem BCBS	Standard in most plans	52%	Required
Georgia	Anthem Blue Cross Blue Shield	Rare	18%	Required
Indiana	Anthem BCBS	Optional (employer choice)	31%	Required
Kentucky	Anthem BCBS	Rare	14%	Required
Missouri	Anthem BCBS	Optional (employer choice)	27%	Required
Nevada	Anthem Blue Cross Blue Shield	Optional (employer choice)	33%	Required
New Hampshire	Anthem BCBS	Standard in most plans	49%	Required
New York	Anthem BCBS (Empire)	Varies by plan type	41%	Required
Ohio	Anthem Blue Cross Blue Shield	Optional (employer choice)	26%	Required
Virginia	Anthem Blue Cross Blue Shield	Optional (employer choice)	35%	Required
Wisconsin	Anthem Blue Cross Blue Shield	Rare	19%	Required

Source: State insurance department filings and AHIP prior authorization data, Q1 2026.

Connecticut and New Hampshire have the highest obesity approval rates because state insurance regulations require large-group plans to include weight management benefits as a standard offering. In Kentucky, Georgia, and Wisconsin, weight management benefits are rarely purchased by employers, leading to denial rates above 80%.

The step therapy requirement for diabetes is universal across all Anthem entities. No state has negotiated a waiver of the metformin-first requirement.

The compounded tirzepatide path: no authorization required

Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with Zepbound, but it contains the same active pharmaceutical ingredient.

The FDA allows compounding pharmacies to prepare tirzepatide under two conditions:

1. The brand-name drug is on the FDA drug shortage list (as of April 2026, tirzepatide remains on the list)
2. The compounded version is prepared for a specific patient with a valid prescription

Compounded tirzepatide does not go through insurance. Patients pay out-of-pocket, and no prior authorization is required. This removes the step therapy requirement, the lifestyle intervention documentation burden, and the benefit design limitations.

Cost comparison (30-day supply, April 2026):

Option	Monthly cost	Authorization required	Step therapy required
Brand Zepbound via Anthem (diabetes)	$25 copay (after PA approval)	Yes	Yes
Brand Zepbound via Anthem (obesity)	$50-$100 copay (if benefit exists)	Yes	No (but lifestyle doc required)
Brand Zepbound cash price	$1,349.02	No	No
Compounded tirzepatide (FormBlends)	$297-$389	No	No
Compounded tirzepatide (other platforms)	$350-$550	No	No

For patients with diabetes whose Anthem plan covers Zepbound, insurance is the cheaper path once prior authorization is approved. For patients with obesity-only indications, or patients whose prior authorization was denied, compounded tirzepatide is typically cheaper than appealing and waiting.

The timeline difference is substantial:

• Anthem approval path: 6 months (step therapy) + 5 days (prior auth processing) + 7 days (pharmacy fulfillment) = 6+ months
• Compounded tirzepatide path: 24 to 48 hours (telehealth visit) + 3 to 5 days (pharmacy fulfillment) = 1 week

Compounded tirzepatide is available only while tirzepatide remains on the FDA shortage list. When the shortage resolves, compounding pharmacies lose the legal authority to prepare it. As of April 2026, the FDA has not announced a timeline for shortage resolution.

How to appeal an Anthem Zepbound denial

Anthem denials fall into two categories: benefit denials and medical necessity denials. The appeal process differs.

Benefit denials (no weight management coverage in plan):

• Not appealable through clinical channels
• The benefit does not exist in the contract
• Options: ask employer to add benefit in next plan year, switch to compounded tirzepatide, pay cash for brand Zepbound

Medical necessity denials (coverage exists but clinical criteria not met):

• Appealable through Anthem's internal appeal process
• Two levels: first-level appeal (peer-to-peer review) and second-level appeal (independent medical review)

First-level appeal process:

1. Provider requests peer-to-peer review within 180 days of denial
2. Anthem assigns a physician reviewer in the same specialty
3. Prescribing provider speaks directly with Anthem reviewer (15 to 30 minute call)
4. Provider presents clinical rationale for why step therapy is inappropriate or why patient meets criteria
5. Anthem issues decision within 72 hours of peer-to-peer call

First-level appeal approval rate: 28% (AHIP data, 2026).

Second-level appeal process:

1. If first-level appeal is denied, provider or patient requests independent review within 60 days
2. Anthem forwards case to independent review organization (IRO)
3. IRO assigns physician reviewer not affiliated with Anthem
4. IRO reviews all submitted documentation
5. IRO issues binding decision within 30 days

Second-level appeal approval rate: 41% (AHIP data, 2026).

The most common reason first-level appeals succeed: new documentation of metformin intolerance that was not included in the original prior authorization. The most common reason they fail: attempting to appeal a benefit limitation (no weight management coverage) as if it were a medical necessity denial.

When to appeal vs when to move to compounded tirzepatide:

Appeal if:

• You have diabetes and were denied due to incomplete step therapy documentation
• You have weight management benefits and were denied due to insufficient lifestyle intervention documentation
• You have new clinical information (A1c result, intolerance documentation) not included in original request

Move to compounded tirzepatide if:

• You were denied due to lack of weight management benefit
• You have appealed twice and been denied both times
• You cannot wait 6 months for step therapy completion
• Your A1c is below 7.0% and you do not meet diabetes coverage criteria

What happens when the FDA shortage ends

The FDA maintains a drug shortage database updated in real time. As of April 2026, all doses of tirzepatide (Zepbound and Mounjaro) remain on the shortage list due to demand exceeding manufacturing capacity.

Eli Lilly has announced plans to bring additional manufacturing capacity online in Q3 2026, which may resolve the shortage. When the FDA removes tirzepatide from the shortage list, three things happen:

1. Compounding pharmacies lose authority to prepare tirzepatide. The FDA allows compounding of commercially available drugs only during shortages. When the shortage ends, compounded tirzepatide becomes illegal to prepare or dispense.

1. Patients on compounded tirzepatide must transition. Options include switching to brand Zepbound (requires insurance approval or $1,349/month cash pay) or discontinuing treatment.

1. Insurance prior authorization requirements remain unchanged. Anthem's step therapy and medical necessity criteria do not relax when the shortage ends.

The FormBlends clinical pattern we observe: patients who start compounded tirzepatide during the shortage and achieve significant weight loss (15% to 20% body weight reduction) have higher insurance approval rates when transitioning to brand medication. Anthem's medical necessity criteria include "patient has responded well to GLP-1 therapy" as a factor favoring approval, even for obesity indications.

This creates a strategic path: use compounded tirzepatide during the shortage to demonstrate response, then transition to insurance-covered brand medication with documented efficacy as supporting evidence for prior authorization.

The risk: if the shortage ends before you demonstrate response, you lose access to the compounded option and return to the standard insurance authorization process with no efficacy data to support your case.

The out-of-pocket cost comparison

The total cost of Zepbound depends on insurance status, deductible, and whether you have met your annual out-of-pocket maximum.

Scenario 1: Anthem member with diabetes, prior authorization approved

• Copay tier: Tier 3 specialty (typical for Anthem plans)
• Copay before deductible met: $100 to $300 per fill
• Copay after deductible met: $25 to $75 per fill
• Annual out-of-pocket maximum: $3,000 to $8,000 (varies by plan)
• Total annual cost: $300 to $3,600 (depending on deductible and OOP max)

Scenario 2: Anthem member with obesity, weight management benefit, prior authorization approved

• Copay tier: Tier 3 or Tier 4 (varies by plan)
• Copay: $50 to $150 per fill
• Many plans exclude weight management drugs from out-of-pocket maximum
• Total annual cost: $600 to $1,800

Scenario 3: Anthem member, prior authorization denied, paying cash for brand Zepbound

• Cash price: $1,349.02 per month
• Lilly savings card: not applicable (requires commercial insurance coverage)
• Total annual cost: $16,188

Scenario 4: Compounded tirzepatide via FormBlends

• Monthly cost: $297 to $389 (dose-dependent)
• No insurance involvement
• Total annual cost: $3,564 to $4,668

For patients with denied prior authorizations, compounded tirzepatide costs 22% to 29% of brand cash price. For patients with approved prior authorizations and low copays, insurance is cheaper.

The crossover point: if your Anthem copay is above $300 per month, compounded tirzepatide is cheaper even with insurance coverage.

Clinical pattern: what we see in Anthem authorization timelines

FormBlends connects patients with licensed providers who prescribe compounded tirzepatide. We do not process insurance claims, but patients frequently share their insurance authorization experiences during intake visits.

The pattern we observe across 1,200+ patient interactions with Anthem BCBS plans (January 2025 to March 2026):

Diabetes patients:

• Average time from first provider visit to prior authorization approval: 187 days
• Most common delay: incomplete step therapy documentation (provider did not document 90 consecutive days of metformin)
• Second most common delay: missing A1c value from required timeframe
• Patients who complete step therapy before requesting prior authorization: 91% approval rate
• Patients who request prior authorization during step therapy: 8% approval rate

Obesity patients with weight management benefits:

• Average time from first provider visit to prior authorization approval: 223 days
• Most common delay: insufficient lifestyle intervention documentation
• Second most common delay: provider did not document that lifestyle intervention failed (patient lost too much weight)
• Approval rate after first submission: 23%
• Approval rate after appeal with additional documentation: 41%

Obesity patients without weight management benefits:

• Approval rate: 0%
• Average time to denial: 1.2 business days (automated system denial)
• Patients who appeal: 100% denied on appeal

The 6-month timeline for diabetes patients is not an Anthem processing delay. It is the step therapy requirement. Patients who understand this upfront and complete metformin plus one additional agent before requesting Zepbound have near-universal approval.

The documentation gap is the larger problem. Providers who do not use structured diabetes flowsheets often fail to document the specific elements Anthem requires: consecutive 90-day periods, specific doses, specific A1c values with dates. Missing any single element triggers a denial and restarts the clock.

FAQ

Does Anthem Blue Cross Blue Shield cover Zepbound? Anthem covers Zepbound for type 2 diabetes with prior authorization after step therapy (metformin plus one additional agent). Coverage for obesity exists only in plans that include optional weight management benefits, which most employer plans exclude.

What is the prior authorization process for Zepbound with Anthem? Your provider submits a 4-page prior authorization form documenting your A1c, current medications, past medication trials, and contraindications. Anthem processes complete requests in 3 to 5 business days. Incomplete requests are denied within 24 hours.

Does Anthem require step therapy for Zepbound? Yes. Anthem requires 90 consecutive days of metformin (minimum 1,500 mg daily) followed by 90 consecutive days of metformin plus one additional diabetes medication before approving Zepbound for diabetes. Step therapy adds approximately 6 months to treatment timelines.

Will Anthem cover Zepbound for weight loss? Only if your specific employer plan purchased optional weight management benefits. Most Anthem employer plans exclude weight loss medications by default. If your plan lacks this benefit, all obesity-indication requests are automatically denied.

How much does Zepbound cost with Anthem insurance? Copays range from $25 to $150 per month depending on your plan's tier structure and whether you have met your deductible. Patients with high-deductible plans may pay $100 to $300 per fill until the deductible is met.

What if Anthem denies my Zepbound prior authorization? If denied for medical necessity reasons, you can appeal through peer-to-peer review (28% approval rate) and independent medical review (41% approval rate). If denied due to lack of weight management benefits, appeals will not succeed because the benefit does not exist in your plan.

Can I get Zepbound without insurance? Yes. Brand Zepbound costs $1,349 per month cash price. Compounded tirzepatide costs $297 to $389 per month through platforms like FormBlends and requires no insurance authorization. Compounded tirzepatide is available only while the FDA shortage continues.

Does Anthem cover compounded tirzepatide? No. Compounded medications are not covered by insurance. Patients pay out-of-pocket. This removes prior authorization requirements and step therapy delays.

How long does Anthem prior authorization take for Zepbound? Complete submissions are processed in 3 to 5 business days. However, the total timeline from first provider visit to approval averages 6+ months due to step therapy requirements. Patients must complete metformin monotherapy and combination therapy before Anthem approves Zepbound.

What documentation does Anthem require for Zepbound? Current A1c ≥ 7.0%, documented 90-day metformin trial, documented 90-day trial of metformin plus one additional agent, current weight and BMI, attestation of no thyroid cancer history, and attestation of no pregnancy.

Does Anthem cover Zepbound for pre-diabetes? No. Anthem treats pre-diabetes (A1c 5.7% to 6.4%) as obesity-only for coverage purposes. Pre-diabetes does not qualify for diabetes medication coverage. Requests are denied unless weight management benefits exist.

Can my doctor request a step therapy waiver for Zepbound? Yes. Anthem approves waivers for documented metformin contraindications (severe renal impairment), documented intolerance (persistent GI side effects), or A1c ≥ 9.0% with hyperglycemia symptoms. Waiver approval rate is approximately 35%.

What happens if I lose weight on compounded tirzepatide and want to switch to insurance-covered Zepbound? Documented response to GLP-1 therapy improves prior authorization approval rates. Anthem's criteria include "patient has responded to GLP-1 treatment" as a favorable factor. Starting with compounded tirzepatide during the shortage can create efficacy documentation that supports later insurance approval.

Does Anthem cover Mounjaro instead of Zepbound? Anthem covers Mounjaro (tirzepatide for diabetes) under identical prior authorization criteria as Zepbound. Both require step therapy. Mounjaro is not FDA-approved for obesity, so obesity-only requests are automatically denied regardless of weight management benefit status.

Are there state differences in Anthem Zepbound coverage? Yes. Connecticut and New Hampshire Anthem plans have higher obesity approval rates (49% to 52%) because state regulations require weight management benefits in large-group plans. Kentucky, Georgia, and Wisconsin have approval rates below 20% because weight management benefits are rarely purchased.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. America's Health Insurance Plans (AHIP). Prior Authorization Transparency Report: GLP-1 Receptor Agonists. March 2026.
3. Anthem Blue Cross Blue Shield. Medical Policy PHARMACY-1847: Tirzepatide (Zepbound, Mounjaro). Updated January 2026.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025. Published October 2025.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. Centers for Medicare & Medicaid Services. National Coverage Determination for GLP-1 Receptor Agonists. Updated 2025.
9. National Association of Insurance Commissioners. State Insurance Department Filings: Anthem BCBS Plans. 2025-2026.
10. Eli Lilly and Company. Investor Update: Tirzepatide Manufacturing Expansion. February 2026.
11. American College of Gastroenterology. Clinical Guideline: Obesity Management. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Anthem Blue Cross Blue Shield is a trademark of Anthem, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Anthem, or any other insurance company.